Stella Diagnostics (Stella Diagnostics) Debt-to-EBITDA : -0.47 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Stella Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.65 Mil. Stella Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.80 Mil. Stella Diagnostics's annualized EBITDA for the quarter that ended in Sep. 2023 was $-3.11 Mil. Stella Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.47.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Stella Diagnostics's Debt-to-EBITDA or its related term are showing as below:

SLDX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.86 Med: 0 Max: 0
Current: -1.86

SLDX's Debt-to-EBITDA is ranked worse than
100% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.915 vs SLDX: -1.86

Stella Diagnostics Debt-to-EBITDA Historical Data

The historical data trend for Stella Diagnostics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Debt-to-EBITDA Chart

Stella Diagnostics Annual Data

Trend

Debt-to-EBITDA

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Debt-to-EBITDA	-	-0.47

Competitive Comparison of Stella Diagnostics's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Stella Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stella Diagnostics's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Stella Diagnostics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Stella Diagnostics's Debt-to-EBITDA falls into.

Stella Diagnostics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Stella Diagnostics's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(	+	)	/	N/A
	=	N/A

Stella Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.648	+	0.798)	/	-3.108
	=	-0.47

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

Stella Diagnostics (OTCPK:SLDX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Stella Diagnostics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.